Drug news
CHMP recommends Edarbi/Ipreziv for Hypertension
The CHMP recommends Edarbi/Ipreziv (azilsartan medoxomil)from Takeda for essential hypertension.Azilsartan medoxomil blocks the angiotensin II type 1 receptors and inhibits the renin angiotensin aldosterone system, reducing blood pressure. The drug was approved by the FDA in February 2011.Takeda sees the drug as the successor to candesartan whose patent will expire in 2012.